Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Final Approval for Lamotrigine Extended-Release Tablets USP, 200 mg, 250 mg, and 300 mg. The company has enclosed a press release in this regard.
The above information is a part of company’s filings submitted to BSE.